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ManagementAbstract Background: The diagnosis of lung cancer is essential to customize the care of patients.
Their management is based on histological diagnosis and extent of disease at time of diagnosis.
Aim of the study: To study the impact of preoperative and postoperative pathological diagnosis
of a group of patients managed for lung cancer.
Patients and methods: This study was a single-center retrospective study. The duration of inclu-
sion was 4 years (1 January 2011–31 December 2014). We compared the preoperative pathological
outcomes of medical procedures and postoperative histological data. Data values were estimated in
percentage.
Results: one hundred patients were included in the study. The concordance rate between preop-
erative and postoperative diagnoses across all histological types, was 68%. The misdiagnosis rate
and incomplete diagnosis rates were 10% and 22%. There were discrepancies regardless of diagnos-
tic histologic type. Concordance rates of endoscopy, the trans-bronchial puncture, echo-endoscopy,
and CT-puncture were 74%, 77%, 46%, and 66% respectively.
Conclusion: Our study shows pre and postoperative discrepancy in nearly 30% of cases. This
finding should be taken into account because it can change the therapeutic management of these
patients in particular of non-operated patients.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
The management of lung cancer is based on histological diag-
nosis and extent of disease at diagnosis, determined by the
TNM [1] classification. Currently, Lung cancer is the mostcommon cancer worldwide, accounting for 1.61 million new
cases annually representing 12.7% of all new cancers. It is also
the most common cause of death from cancer, with 1.38 mil-
lion deaths (18.2% of the total). The majority of the cases
now occur in the developing countries (55%) [2]. Lung cancer
is ranked fifth among male population and thirteenth among
female population. It affected (73.6%) males and (26.4%)
females with a male to female ratio of 279:100 [3]. Three quar-
ters of patients with non-small cell lung cancer are diagnosed
with locally advanced (stage IIIB) or metastatic (stage IV),Tuberc.
Table 2 Surgical techniques used for diagnosis.







2 A.E. Sileem et al.unresectable [3]. Chemotherapy for these patients is the pri-
mary therapeutic option. The choice of a different protocol
of chemotherapy regimens is guided largely by histological typ-
ing and immunohistochemical profile of the tumor so the treat-
ment is specific for each cell type: small cell carcinoma,
squamous cell carcinoma and adenocarcinoma. During the last
decade, researches, including genetic, have enabled the devel-
opment of targeted therapies. Patients with adenocarcinoma
can currently benefit from specific treatments based on tumor
mutations. The individualization of these biomarkers has
amended decision algorithms therapist. Having a reliable diag-
nosis has become essential to customize the care of patients.
The vast majority of lung cancer diagnoses is obtained from
small biopsies performed during non-surgical procedures.
The small size of samples and the small amount of tissue
obtained from these methods can make it difficult or impossi-
ble for the achievement of all pathological examinations. The
reliability of the diagnosis can then be questioned.
Patients and methods
This study was a single-center retrospective study. The dura-
tion of inclusion was 4 years (1 January 2011–31 December
2014). In total, 200 patients were followed up in our hospital
for lung cancer. 150 had had a surgery for diagnostic or ther-
apeutic purposes at cardiothoracic department Zagazig univer-
sity hospital. Of these, 100 who had a preoperative diagnosis
were included in this study.
The objective of this study was to verify the correlation
between the preoperative and postoperative histological diag-
nosis. A preoperative diagnosis of lung carcinoma formal
had to be obtained by medical method (bronchoscopy,
Trans-bronchial aspiration (TBNA), Sputum cytology and
Computed tomography (CT) C-T guided biopsy). The final
diagnosis was obtained only through surgical method (wedge
resection, pleural biopsies, segmentectomy, lobectomy, pneu-
monectomy, lymph node biopsies). Each patient had a com-
plete sheet, including: a physical examination, chest
radiography (anteroposterior and lateral), a chest CT, abdom-
inal and brain, and fiber optic Rigid bronchoscopy. The oper-
ability sheet included: ECG, pulmonary function tests, a gas
analysis, and laboratory tests. Where necessary, more complex
explorations complete the assessment: cardiac ultrasound, car-
diac and cardiopulmonary effort test, myocardial perfusion
and ventilation/perfusion scan. For each patient we studied
preoperative histological type, preoperative diagnostic
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other than lung cancer and patients with no preoperative
diagnosis. According to this we divide the patients into:
Group 1-concordant diagnosis: pre and postoperative histol-
ogy is identical. Group 2-misdiagnosis: unconfirmed final diag-
nosis of cancer or different pre- and postoperative histological
types. Group 3-incomplete diagnosis: a final diagnosis of
tumor is of composite histology or undifferentiated tumor,
to be specified by surgery. The results of the matches were
expressed as a percentage.
Results
Table 1: Diagnostic methods. One hundred patients were
included in the study. The average age was 62 years. 75 were
male (75%) and 25 were women (25%). Preoperative diag-
noses were obtained by 61 fiber optic bronchoscopes, 14
TBNA, 6 sputum cytology, 19 Computed tomography (CT)
guided biopsy.
Table 2: Surgical techniques used for diagnosis. Postopera-
tive diagnoses were obtained by lobectomy in 56 patients
(56%), pneumonectomy 17, 1 pleuropneumonectomy total of
18 patients (18%), 8 segmentectomy and atypical resections
(8%), 4 pleural biopsy (4%), 14 video mediastinoscopy and
mediastinal exploration (14%).
Table 3 Group of patients and concordance. Patients were
classified into 3 groups: (concordant Group 1): The preopera-
tive histology is corresponding to the definitive diagnosis in 68
patients (68%). (Group 2): The preoperative misdiagnosis is
presented in ten patients (10%). (Group 3): The preoperative
diagnosis was incomplete in 22 patients (22%).
Table 4 and Fig. 1 Pre-and post-operative diagnostic
pathology. The preoperative histology is corresponding to
the definitive diagnosis (concordant Group 1) in 68 patients
(68%): 29 patients adenocarcinoma (42.6%); 30 patients squa-
mous cell carcinomas (44.1%); 4 carcinoid tumors (2 typical
and 2 atypical) (6%); 2 small cell carcinomas (SCC) (2.9%);
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Table 4 Pre-and post-operative diagnostic pathology.
Pathology Adenocarcinoma Sq.cell.CA Carcinoid Small cell CA Sarcoma N.S.C.CA
Total No. 38 37 4 3 2 16
Post.Op.other path. 9–24% 7–19% 4–100% 2–67% 0–0% 6–37.5%
Post.Op. Confirmed path. 29–67% 30–81% 4–100% 1–33% 1–50% 10–62.5%
Figure 1 Pre–post-operative pathological diagnosis.
Pre and post operative diagnosis of lung cancer patients: Is there a concordance? 3coma (1.5%). The preoperative misdiagnosis (Group 2) is pre-
sented in ten patients (10%): 4 patients had different pre and
postoperative diagnoses (4%); 6 patients (6%) had a diagnosis
of fibro elastic scar with no residual tumor found in the surgi-
cal specimen. The preoperative diagnosis was incomplete
(Group 3) in 22 patients (22%). 12 patients (12%) had final
a diagnosis of composite tumor, having at least two histologi-
cal subtypes. For 10 patients (10%) with an initial diagnosis of
undifferentiated carcinoma, surgery could specify the histolog-
ical type. Concordance rate of pre and postoperative diagnoses
varies depending on the histological type: The preoperative
diagnosis of histological type of adenocarcinoma is presented
in 38 patients, 29 patients of them have confirmed diagnosis
by surgery (76%), 6 patients had an incomplete diagnosis cor-
responding to a composite tumor (16%) (4 tumors consider it
to its lipid component, 1 has a neuroendocrine large cell com-
ponent, and 1 has a sarcomatoid component), 3 patients (8%)
had misdiagnosis. 3 adenocarcinoma were ultimately different
histological lesions (1 patient had sarcomatoid carcinoma, 1
patient had a large cell carcinoma and 1 patient had small cell
carcinomas). The preoperative diagnosis of histological type of
squamous cell carcinoma is presented in 37 patients, 30
patients of them have confirmed diagnosis by surgery (81%).
2 patients with squamous cell carcinoma had a composite
tumor (5%) (In one patient is linked to basal cell adenocarci-Table 5 Non-surgical methods for pathological diagnosis and its id
Non-surgical Methods of diagnosis Fiber optic endoscope
Total No. of Pts. 101
No. of Pre.op. diagnosis 61
Identical path.pre.Post.op. 45
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noma), 5 patients were misdiagnosed (14%) in 2 patients, the
diagnosis was different (2 patients with squamous cell carci-
noma had finally adenocarcinoma, non-small cell lung cancer)
and the other 3 patients had fibro elastic scar.
The preoperative diagnosis of histological type of carcinoid
tumor, was confirmed in 100% of cases. We have 4 patients (2
typical and 2 atypical).
Three patients had a preoperative diagnosis of small cell
carcinoma and the diagnosis was confirmed on 2 separate ses-
sions, a concordance rate of 67%. In one case (33%), the final
tumor histology was a composite tumor combining component
of a small cell carcinoma and adenocarcinoma component.
Two patients had a preoperative diagnosis of sarcomatoid
tumor. The diagnosis was confirmed in 50% of cases. 1 patient
had a preoperative diagnosis of large cell carcinoma. The final
diagnosis was an adenocarcinoma (concordance rate of 0%).
The preoperative diagnosis of histological type of non-
small cell carcinoma, was presented in 16 patients, 7 of non-
small cell carcinoma patients (43.6%) had adenocarcinoma,
2 patients (12.5%) had squamous cell carcinoma, 1 patient
(6.3%) had small cell carcinoma, 1 patient (6.3%) had large
cell carcinoma, two patients (12.5%) had composite tumor, 2
patients (12.5%) had fibro elastic scar and in one patient
(6.3%), it could not be specified by surgery.
Tables 5 and 6 and Figs. 2 and 3: The pre and postoperative
histological concordance rates also vary depending on the
diagnostic methods. Among the 101 patients who underwent
endoscopy, preoperative diagnosis was obtained by this
method in 61 patients (60.4%). The pre and postoperative his-
tology were identical in 45 cases, with a concordance rate of
74%. The sensitivity of bronchoscopy was 45%. The cancer
diagnosis was wrong in 10 patients (9.9%): 7 patients (7%)
had different diagnoses and 3 patients (3%) had a fibro elastic
scar.
In 30 cases (29.7%), the preoperative diagnosis was incom-
plete: 15 patients had a histological result of composite tumor
(15%) and 15 other had preoperative diagnosis of non-small
cell lung cancer (surgery has helped to specify the diagnosis).
Eighteen patients underwent a TBNA. Fourteen Preopera-
tive diagnoses were obtained by this method (78%). In 10
patients (71% concordant rate), the final histological findings
corresponded to preoperative diagnoses. The sensitivity of
TBNA was 55.5%. In 2 cases the diagnosis was wrong. In
other 2 patients, the diagnosis is unclear.entical results for Post.Op.Results.
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Table 6 Concordance and sensitivity of non-surgical methods of diagnosis.
Fiber optic endoscope (%) TBNA (%) Sputum cytology (%) C-T guided biopsy (%)
Concordance rate 74 71 33 68
Sensitivity 45 55.50 25 68
Figure 2 Non surgical methods for pathological diagnosis and
its identical results for Post.op. results.
Figure 3 Concordance and sensitivity of nom-surgical methods
of diagnosis.
4 A.E. Sileem et al.Eight patients who had sputum cytology 6 Preoperative
diagnoses were confirmed by this method (75%). In 2 cases,
definitive diagnoses were consistent with histological postoper-
ative diagnostics, a concordance rate of 33%. The sensitivity of
sputum cytology was 25%. In 3 patients, the initial diagnosis
was unclear. In one patient the diagnosis was wrong.
Nineteen patients underwent CT-puncture and had a pre-
operative diagnosis obtained by this method. In 13 cases, the
final histological findings corresponded to preoperative diag-
nosis, with a concordance rate of 68%. The sensitivity of this
review was also 68%. In 32% of cases the diagnosis was either
incorrect or not specified. in one case (5%), the initial
diagnosis was wrong; in 2, the final diagnosis was that of a
fibro-elastic scar (11%); in 2 (11%), the final diagnosis was a
composite tumor; in one patient had initial diagnosis of non-
small lung cancer (5%); surgery could clarify the diagnosis.
Discussion
Over time, the histological classification of lung cancer has
evolved and become more complex, taking into account the
histological data, immunohistochemical and genetic. There
are four major forms of lung cancer (squamous cell carcinoma,
adenocarcinoma, large cell carcinoma and small cell
carcinoma) described by Kreyberg in 1967 [4], we currently
have many histological types and subtypes, illustrating the
heterogeneity of primary lung carcinoma [5,6]. Thus, the
survivals are different depending on the type and histologicPlease cite this article in press as: A.E. Sileem et al., Pre and post operative diagnosi
(2016), http://dx.doi.org/10.1016/j.ejcdt.2016.08.013subtype: Yim et al. [7] as well as other studies [8,9] showed that
patients with a lipoid adenocarcinoma or having a lipoid com-
ponent have a significantly higher survival of patients with
invasive type of adenocarcinoma. Kawase et al. studies [10]
and Asamura et al. [11] showed significant differences in sur-
vival according to histology (adenocarcinoma and squamous
cell carcinoma). The chemotherapy protocols also differ
according to histological type: Scagliotti et al. [12] concluded
that cisplatin-pemetrexed combination brings a benefit in terms
of survival for patients with adenocarcinoma. Similarly, molec-
ular biology has enabled the development of targeted therapies
to individualize patient treatment. Studies have shown that
patients with adenocarcinoma and EGFR mutation carriers
have a gain in survival when treated with targeted therapies
[13,14]. In addition, no benefit in terms of survival or other
clinically relevant effects of tyrosine kinase inhibitor therapy
has been demonstrated in patients with EGFR expression as
negative. The search for EGFR mutations can be performed
on any biological sample containing tumor cells, and profitabil-
ity will depend on the abundance of tumor cells, the amount of
material available, the representativeness of the molecular
abnormality described as well as the technique used. To do this
research on small biopsy material, a cytological sampling and
on a surgical specimen. However, as regards the first two types
of samples, material management by the pathologist is essential
to enable the achievement of the different techniques that qual-
ify the tumor material [15]. Having a reliable histological diag-
nosis has become paramount or more important than anything
else but most of them are obtained by non-surgical methods,
which may have consequences in terms of reliability [16].
Finally, within our multidisciplinary consultation meetings, it
is not uncommon to find a discrepancy between the preopera-
tive diagnosis and postoperative diagnosis. These reasons
motivated us to perform this study, especially since few studies
have verified the consistency of pre and postoperative diag-
noses and most are interested only distinguish between small
cell carcinoma and non-small cell carcinoma [17].
Concordance rate between pre and postoperative histolog-
ical types in our study is 68%. In almost one third of cases,
the preoperative diagnosis is either wrong or incomplete. This
high discrepancy shows that having a reliable diagnosis is not
obvious. In case of doubt about the quality of the examination
done, the creation of new biopsies should be done.
In our study, non-surgical methods explorers have not
made the diagnosis in 16% cases (adenocarcinoma). These
patients without diagnosis from surgical biopsies, have not
benefited from adequate adjuvant treatment and the biomark-
ers tests would not have been realized. These non-diagnostic
results therefore have important therapeutic implications.
These errors also apply to other histological types.
Their consequences are not insignificant since the beginning
of research to explore the interest of biomarker research of
mutations, including squamous cell carcinoma [13]. Several
hypotheses can be advanced to explain this discrepancy: Dues of lung cancer patients: Is there a concordance?, Egypt. J. Chest Dis. Tuberc.
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general [18], the small biopsies may not be representative of
the tumor as a whole. The main difficulty in the classification
of poorly differentiated tumors, differentiated component
which is difficult or impossible to appreciate given the small
size of samples. The second difficulty concerns the so-called
composite or mixed tumors.
In our trial, they represent 10% of the lesions. The main
problem is the almost exclusive presence of a determinant
quantity of tumor at a biopsy [19]. The small amount of tumor
tissue obtained from non-surgical procedures can make it diffi-
cult or impossible the achievement of all histological analyzes,
immunological and genetic due to the ‘‘exhaustion” of the
blocks.
Currently, there are no prospective data assessing the
amount of tumor tissue obtained according to the used sam-
pling techniques. The amount of tissue also influences the qual-
ity of examinations performed. Moreover, in a study
comparing the expression of biomarkers based on the type of
sample technique (bronchial biopsy versus surgical specimen)
in patients with adenocarcinoma, Cutter et al. [20] show a dis-
crepancy in EGFR expression significantly.
Our study has several limitations: it is a retrospective trial,
single-center whose small population limits the power of the
study. However, other trials with more staff and made in sev-
eral centers could help confirm or not our results.
Conclusion
The message of our study is not to say that surgery should be
the only diagnostic tool in the management of lung cancer.
However, account must be taken of the discrepancy between
the preoperative diagnosis and postoperative diagnosis
observed in our trial to be able to propose if necessary the cre-
ation of new biopsies to clarify a diagnosis or to check for
biomarkers in order to adapt a therapeutic protocol. If in
the near future, the development of techniques allow a refine-
ment of diagnosis from a smaller amount of tumor tissue, we
must now focus on methods to achieve maximum material
and with minimum risk to patients.Conflict of Interest
There is no conflict of interest.
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